JP2019514903A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514903A5 JP2019514903A5 JP2018555938A JP2018555938A JP2019514903A5 JP 2019514903 A5 JP2019514903 A5 JP 2019514903A5 JP 2018555938 A JP2018555938 A JP 2018555938A JP 2018555938 A JP2018555938 A JP 2018555938A JP 2019514903 A5 JP2019514903 A5 JP 2019514903A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- azabicyclo
- methyl
- pyrazol
- nonan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 88
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 72
- -1 oct-8-yl Chemical group 0.000 claims description 63
- 150000001875 compounds Chemical class 0.000 claims description 61
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 32
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 24
- 125000004076 pyridyl group Chemical group 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 21
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 18
- 241000124008 Mammalia Species 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- 208000027866 inflammatory disease Diseases 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 10
- 125000001153 fluoro group Chemical group F* 0.000 claims description 10
- PBIUUJCEMUAWJJ-UHFFFAOYSA-N azetidine-3-carbonitrile Chemical compound N#CC1CNC1 PBIUUJCEMUAWJJ-UHFFFAOYSA-N 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 8
- UCTUKXLCLYHJME-QBZDVNTPSA-N 1-[[(1R,5S)-3-[[4-[[5-(hydroxymethyl)pyrazolidin-3-yl]amino]-6-methoxypyrimidin-2-yl]-methylamino]-9-azabicyclo[3.3.1]nonan-9-yl]sulfonyl]azetidine-3-carbonitrile Chemical compound COc1cc(NC2CC(CO)NN2)nc(n1)N(C)C1C[C@@H]2CCC[C@H](C1)N2S(=O)(=O)N1CC(C1)C#N UCTUKXLCLYHJME-QBZDVNTPSA-N 0.000 claims description 7
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- 125000002393 azetidinyl group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 6
- 239000011541 reaction mixture Substances 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 claims description 4
- ZMBLTLSKPTWFEZ-QBZDVNTPSA-N 2-methylpropyl (1R,5S)-3-[[4-[[5-(hydroxymethyl)pyrazolidin-3-yl]amino]-6-methoxypyrimidin-2-yl]-methylamino]-9-azabicyclo[3.3.1]nonane-9-carboxylate Chemical compound COc1cc(NC2CC(CO)NN2)nc(n1)N(C)C1C[C@@H]2CCC[C@H](C1)N2C(=O)OCC(C)C ZMBLTLSKPTWFEZ-QBZDVNTPSA-N 0.000 claims description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- GGRFGFBPDXMJFO-PVOWQQPYSA-N [5-[[6-methoxy-2-[[(1R,5S)-9-(2-methoxyethylsulfonyl)-9-azabicyclo[3.3.1]nonan-3-yl]-methylamino]pyrimidin-4-yl]amino]pyrazolidin-3-yl]methanol Chemical compound COCCS(=O)(=O)N1[C@H]2CCC[C@@H]1CC(C2)N(C)c1nc(NC2CC(CO)NN2)cc(OC)n1 GGRFGFBPDXMJFO-PVOWQQPYSA-N 0.000 claims description 4
- GTOQQHCRYJBYEX-PCQUJAHOSA-N [5-[[6-methoxy-2-[methyl-[(1R,5S)-9-methylsulfonyl-9-azabicyclo[3.3.1]nonan-3-yl]amino]pyrimidin-4-yl]amino]pyrazolidin-3-yl]methanol Chemical compound COc1cc(NC2CC(CO)NN2)nc(n1)N(C)C1C[C@@H]2CCC[C@H](C1)N2S(C)(=O)=O GTOQQHCRYJBYEX-PCQUJAHOSA-N 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- RLDWUPNOCFQQOB-WPSIBSQOSA-N 5-[[(1S,5R)-3-[[4-[[5-(hydroxymethyl)pyrazolidin-3-yl]amino]-6-methoxypyrimidin-2-yl]-methylamino]-9-azabicyclo[3.3.1]nonan-9-yl]methyl]pyridine-3-carbonitrile Chemical compound COc1cc(NC2CC(CO)NN2)nc(n1)N(C)C1C[C@@H]2CCC[C@H](C1)N2Cc1cncc(c1)C#N RLDWUPNOCFQQOB-WPSIBSQOSA-N 0.000 claims description 2
- KKKIEHCMACYQKK-XTFVGRHZSA-N 5-[[(1S,5R)-3-[[4-[[5-(hydroxymethyl)pyrazolidin-3-yl]amino]-6-methoxypyrimidin-2-yl]amino]-9-azabicyclo[3.3.1]nonan-9-yl]methyl]pyridine-2-carbonitrile Chemical compound COc1cc(NC2CC(CO)NN2)nc(NC2C[C@@H]3CCC[C@H](C2)N3Cc2ccc(nc2)C#N)n1 KKKIEHCMACYQKK-XTFVGRHZSA-N 0.000 claims description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- 239000013078 crystal Substances 0.000 claims description 2
- AUQDITHEDVOTCU-UHFFFAOYSA-N cyclopropyl cyanide Chemical compound N#CC1CC1 AUQDITHEDVOTCU-UHFFFAOYSA-N 0.000 claims description 2
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims description 2
- LCEDQNDDFOCWGG-UHFFFAOYSA-N morpholine-4-carbaldehyde Chemical compound O=CN1CCOCC1 LCEDQNDDFOCWGG-UHFFFAOYSA-N 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000006413 ring segment Chemical group 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 0 *Nc1nc(Nc2n[n]c(CO)c2)cc(O*)n1 Chemical compound *Nc1nc(Nc2n[n]c(CO)c2)cc(O*)n1 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- BPVYRJYKOVEFOW-UHFFFAOYSA-N COC1=NC=NC(=C1)NC2=NNC(=C2)CO Chemical compound COC1=NC=NC(=C1)NC2=NNC(=C2)CO BPVYRJYKOVEFOW-UHFFFAOYSA-N 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662328737P | 2016-04-28 | 2016-04-28 | |
| US62/328,737 | 2016-04-28 | ||
| PCT/US2017/029796 WO2017189822A1 (en) | 2016-04-28 | 2017-04-27 | Pyrimidine compounds as jak kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514903A JP2019514903A (ja) | 2019-06-06 |
| JP2019514903A5 true JP2019514903A5 (enExample) | 2020-04-23 |
| JP6881879B2 JP6881879B2 (ja) | 2021-06-02 |
Family
ID=58672793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555938A Active JP6881879B2 (ja) | 2016-04-28 | 2017-04-27 | Ｊａｋキナーゼ阻害剤としてのピリミジン化合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10028960B2 (enExample) |
| EP (1) | EP3433253B1 (enExample) |
| JP (1) | JP6881879B2 (enExample) |
| KR (1) | KR102244257B1 (enExample) |
| CN (1) | CN109071529B (enExample) |
| AU (1) | AU2017258186B2 (enExample) |
| BR (1) | BR112018072168A2 (enExample) |
| CA (1) | CA3020506A1 (enExample) |
| CL (1) | CL2018003060A1 (enExample) |
| CO (1) | CO2018011408A2 (enExample) |
| DK (1) | DK3433253T3 (enExample) |
| EA (1) | EA035226B1 (enExample) |
| ES (1) | ES2779880T3 (enExample) |
| IL (1) | IL262386B (enExample) |
| MX (1) | MX377180B (enExample) |
| PT (1) | PT3433253T (enExample) |
| SG (1) | SG11201809342YA (enExample) |
| TW (1) | TWI726094B (enExample) |
| WO (1) | WO2017189822A1 (enExample) |
| ZA (1) | ZA201807179B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2924698T3 (es) | 2015-05-28 | 2022-10-10 | Theravance Biopharma R&D Ip Llc | Proceso e intermedios para la preparación de compuestos de naftiridina como inhibidores de quinasa JAK |
| EP3831830A1 (en) | 2015-11-03 | 2021-06-09 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| DK3712152T3 (da) | 2015-11-03 | 2021-03-22 | Topivert Pharma Ltd | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer |
| WO2017189822A1 (en) * | 2016-04-28 | 2017-11-02 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compounds as jak kinase inhibitors |
| MA49956B1 (fr) | 2017-10-27 | 2022-11-30 | Theravance Biopharma R&D Ip Llc | Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak |
| US12171764B2 (en) | 2018-06-20 | 2024-12-24 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor |
| TWI740288B (zh) * | 2018-11-27 | 2021-09-21 | 大陸商江蘇豪森藥業集團有限公司 | 含氮雜芳類衍生物調節劑、其製備方法和應用 |
| CN115925705B (zh) * | 2018-11-30 | 2024-12-31 | 江苏豪森药业集团有限公司 | 杂芳类衍生物调节剂、其制备方法和应用 |
| JP7482152B2 (ja) * | 2019-04-24 | 2024-05-13 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | 皮膚疾患の処置のためのピリミジンｊａｋ阻害剤 発明の背景 |
| JP7470713B2 (ja) * | 2019-04-24 | 2024-04-18 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物 |
| TW202207918A (zh) * | 2020-05-14 | 2022-03-01 | 美商施萬生物製藥研發Ｉｐ有限責任公司 | 腸道選擇性ｊａｋ３抑制劑的投與 |
| TW202233636A (zh) * | 2020-10-09 | 2022-09-01 | 美商賽若凡斯生物製藥研發智財有限責任公司 | 製備泛ｊａｋ抑制劑之方法及相關中間化合物 |
| WO2022083687A1 (zh) * | 2020-10-21 | 2022-04-28 | 南京明德新药研发有限公司 | 硒杂环类化合物及其应用 |
| WO2023011359A1 (zh) * | 2021-08-05 | 2023-02-09 | 南京明德新药研发有限公司 | 桥环类化合物及其应用 |
| CN113883920B (zh) * | 2021-10-25 | 2024-01-23 | 安徽华铂再生资源科技有限公司 | 一种降低空分装置空冷塔出口温度的方法 |
| WO2023202706A1 (zh) * | 2022-04-21 | 2023-10-26 | 南京明德新药研发有限公司 | 硒杂环类化合物的盐型和晶型及其应用 |
| WO2025040148A1 (zh) * | 2023-08-22 | 2025-02-27 | 北京普祺医药科技股份有限公司 | 一种用于jak抑制剂的外用凝胶及其用途 |
| TW202515852A (zh) * | 2023-09-15 | 2025-04-16 | 美商莫菲克醫療股份有限公司 | 抑制人類整合素α４β７ |
| US12684500B2 (en) | 2024-01-17 | 2026-07-14 | T-Mobile Usa, Inc. | Dynamic scheduling request framework for HP UE SAR reduction |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| BR0116493A (pt) | 2000-12-21 | 2003-09-30 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
| US8211929B2 (en) * | 2004-12-30 | 2012-07-03 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| ATE508126T1 (de) | 2005-11-16 | 2011-05-15 | Vertex Pharma | Als kinaseinhibitoren geeignete aminopyrimidine |
| TW200817391A (en) | 2006-06-30 | 2008-04-16 | Astrazeneca Ab | Novel compounds |
| AU2007269540B2 (en) | 2006-07-05 | 2013-06-27 | Exelixis, Inc. | Methods of using IGF1R and Abl kinase modulators |
| RU2014129740A (ru) | 2011-12-22 | 2016-02-10 | Ф.Хоффманн-Ля Рош Аг | Производные 2,4-диаминопиримидина в качестве ингибиторов серин/треонин киназы |
| WO2015094803A1 (en) * | 2013-12-16 | 2015-06-25 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| NO2721710T3 (enExample) * | 2014-08-21 | 2018-03-31 | ||
| ES2924698T3 (es) | 2015-05-28 | 2022-10-10 | Theravance Biopharma R&D Ip Llc | Proceso e intermedios para la preparación de compuestos de naftiridina como inhibidores de quinasa JAK |
| WO2017189822A1 (en) * | 2016-04-28 | 2017-11-02 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compounds as jak kinase inhibitors |
-
2017
- 2017-04-27 WO PCT/US2017/029796 patent/WO2017189822A1/en not_active Ceased
- 2017-04-27 AU AU2017258186A patent/AU2017258186B2/en not_active Ceased
- 2017-04-27 US US15/498,803 patent/US10028960B2/en not_active Expired - Fee Related
- 2017-04-27 CA CA3020506A patent/CA3020506A1/en not_active Abandoned
- 2017-04-27 DK DK17722324.5T patent/DK3433253T3/da active
- 2017-04-27 CN CN201780026437.4A patent/CN109071529B/zh not_active Expired - Fee Related
- 2017-04-27 EP EP17722324.5A patent/EP3433253B1/en active Active
- 2017-04-27 ES ES17722324T patent/ES2779880T3/es active Active
- 2017-04-27 PT PT177223245T patent/PT3433253T/pt unknown
- 2017-04-27 EA EA201892436A patent/EA035226B1/ru unknown
- 2017-04-27 KR KR1020187034319A patent/KR102244257B1/ko not_active Expired - Fee Related
- 2017-04-27 MX MX2018013191A patent/MX377180B/es active IP Right Grant
- 2017-04-27 JP JP2018555938A patent/JP6881879B2/ja active Active
- 2017-04-27 BR BR112018072168-9A patent/BR112018072168A2/pt not_active Application Discontinuation
- 2017-04-27 TW TW106114033A patent/TWI726094B/zh not_active IP Right Cessation
- 2017-04-27 SG SG11201809342YA patent/SG11201809342YA/en unknown
-
2018
- 2018-06-21 US US16/014,233 patent/US10485803B2/en active Active
- 2018-10-15 IL IL262386A patent/IL262386B/en unknown
- 2018-10-25 CO CONC2018/0011408A patent/CO2018011408A2/es unknown
- 2018-10-26 ZA ZA2018/07179A patent/ZA201807179B/en unknown
- 2018-10-26 CL CL2018003060A patent/CL2018003060A1/es unknown
-
2019
- 2019-10-18 US US16/656,927 patent/US11110095B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11529356B2 (en) | 2-(morpholin-4-yl)-1,7-naphthyridines | |
| TWI921912B (zh) | Fgfr抑制劑及其使用方法 | |
| CA3011189C (en) | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines | |
| JP6899063B2 (ja) | 統合ストレス経路のモジュレーター | |
| TWI662025B (zh) | 用作激酶抑制劑的二芳基醯胺化合物 | |
| AU2015299173A1 (en) | 2-(morpholin-4-yl)-l,7-naphthyridines | |
| JP2016523973A5 (enExample) | ||
| JP2013523884A5 (enExample) | ||
| KR20130129244A (ko) | 치환된 6,6-융합된 질소 헤테로환형 화합물 및 이의 용도 | |
| JP2017526622A (ja) | ３−アミノ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類 | |
| JP2017527585A (ja) | Ｒａｆキナーゼ阻害剤としての化合物および組成物 | |
| TW201838981A (zh) | 嘧啶基-吡啶氧基-萘基化合物以及治療ire1相關之疾病及病症的方法 | |
| WO2012016993A1 (en) | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents | |
| JP2017526720A (ja) | キナーゼ阻害剤としての化合物および組成物 | |
| JP2020512401A (ja) | Ｇｐｒ６のモジュレーターとしてのピペリジニルおよびピペラジニル置換された複素芳香族カルボキサミド | |
| WO2017102091A1 (en) | Heteroarylbenzimidazole compounds | |
| JP2024522588A (ja) | 抗がん化合物 | |
| JP2020533319A (ja) | シクロオレフィン置換複素芳香族化合物およびそれらの使用 | |
| US10774083B2 (en) | Heterocyclic amide compound | |
| HK40109090A (en) | Cycloolefin substituted heteroaromatic compounds and their use | |
| HK40096142A (en) | Cycloolefin substituted heteroaromatic compounds and their use | |
| OA21052A (en) | Cycloalkyl pyrimidines as ferroportin inhibitors. | |
| TW201524969A (zh) | 葡萄糖轉運抑制劑 |